Founded in 2015 and headquartered in Melbourne, Australia, Tarnagulla Ventures focuses on investing in healthcare startups with promising technology, particularly those that can bring their innovations to the US market. The firm has a track record of investing in companies in the biopharma and biotechnology fields, with successful portfolio startups like Inversago Pharma. Tarnagulla Ventures typically invests in companies that are 2-3 years old and participates in rounds with 4 other investors, with deal sizes ranging from 1 to 5 million dollars. While the firm is global in scope, it places a strong emphasis on providing strategic value to its portfolio companies beyond just financial capital.